Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An eosinophilic gastroenteritis that is characterized by inflammation of the stomach.
Biomarker and diagnostic research for eosinophilic gastritis has been reported in the published literature.
No approved treatments are currently available for eosinophilic gastritis. An additional 2 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for eosinophilic gastritis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for eosinophilic gastritis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
4 clinical trials registered, 3 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 PHASE2. Research is sponsored by a mix of industry and academic institutions.
59 publications have been identified in PubMed for eosinophilic gastritis. Research spans Review / Meta-Analysis (25%), Case Report / Case Series (25%), and Epidemiology / Natural History (25%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 15 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:56 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Designated
Exclusivity End |
|---|
Designation Status |
|---|
Benralizumab | Benralizumab | AstraZeneca Pharmaceuticals LP | 2021 | — | Withdrawn |
humanized non-fucosylated anti-siglec-8 monoclonal antibody (IgG1) | humanized non-fucosylated anti-siglec-8 monoclonal antibody (IgG1) | Allakos, Inc. | 2018 | — | Withdrawn |
Gene therapy approaches for eosinophilic gastritis have been reported in the published literature.
4 trials found
Patient case studies | 15 | 25% |
Disease patterns and progression | 15 | 25% |
Clinical study results | 4 | 7% |
Laboratory research | 4 | 7% |
Testing and diagnosis research | 3 | 5% |
New treatment approaches | 3 | 5% |
Rossi CM (2026). [PMID: 41689485](https://pubmed.ncbi.nlm.nih.gov/41689485/). *Current opinion in allergy and clinical immunology*. [Review / Meta-Analysis]
Aleman S (2026). [PMID: 41843038](https://pubmed.ncbi.nlm.nih.gov/41843038/). *Digestive diseases and sciences*. [Epidemiology / Natural History]
Goel M (2026). [PMID: 31613509](https://pubmed.ncbi.nlm.nih.gov/31613509/). *Unknown Journal*. [Review / Meta-Analysis]
Piccirillo M (2026). [PMID: 42051955](https://pubmed.ncbi.nlm.nih.gov/42051955/). *Front Pediatr*. [Case Report / Case Series]
Dudzik J (2026). [PMID: 42110122](https://pubmed.ncbi.nlm.nih.gov/42110122/). *JPGN Rep*. [Case Report / Case Series]
Anstey K (2026). [PMID: 42176737](https://pubmed.ncbi.nlm.nih.gov/42176737/). *J Allergy Clin Immunol Pract*. [Gene Therapy / Novel Therapeutics]
Grueso-Navarro E (2026). [PMID: 42196811](https://pubmed.ncbi.nlm.nih.gov/42196811/). *Diagnostics (Basel)*. [Epidemiology / Natural History]
Hindy J (2026). [PMID: 41736617](https://pubmed.ncbi.nlm.nih.gov/41736617/). *Harefuah*. [Case Report / Case Series]
Visaggi P (2026). [PMID: 41288538](https://pubmed.ncbi.nlm.nih.gov/41288538/). *Gastroenterology*. [Review / Meta-Analysis]
Sánchez-Ramírez A (2026). [PMID: 41695062](https://pubmed.ncbi.nlm.nih.gov/41695062/). *JPGN reports*. [Clinical Trial Publication]
AI-curated news mentioning eosinophilic gastritis
Updated Sep 18, 2026
A recent study highlights the significant burden of eosinophilic gastritis, emphasizing diagnostic challenges and unmet needs in patient care. The findings call for increased awareness and research to address these gaps in understanding and managing the disease.